These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16672550)

  • 1. Differential mucosal susceptibility in HIV-1 transmission and infection.
    Moutsopoulos NM; Greenwell-Wild T; Wahl SM
    Adv Dent Res; 2006 Apr; 19(1):52-6. PubMed ID: 16672550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral transmission of HIV, reality or fiction? An update.
    Campo J; Perea MA; del Romero J; Cano J; Hernando V; Bascones A
    Oral Dis; 2006 May; 12(3):219-28. PubMed ID: 16700731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral mucosal immunity and HIV infection: current status.
    Challacombe SJ; Sweet SP
    Oral Dis; 2002; 8 Suppl 2():55-62. PubMed ID: 12164661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous mucosal antiviral factors of the oral cavity.
    Shugars DC
    J Infect Dis; 1999 May; 179 Suppl 3():S431-5. PubMed ID: 10099113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the oral environment in HIV-1 transmission.
    Shugars DC; Wahl SM
    J Am Dent Assoc; 1998 Jul; 129(7):851-8. PubMed ID: 9685760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I.
    Wahl SM; McNeely TB; Janoff EN; Shugars D; Worley P; Tucker C; Orenstein JM
    Oral Dis; 1997 May; 3 Suppl 1():S64-9. PubMed ID: 9456660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of HIV infection on oral mucosal immunity.
    Challacombe SJ; Naglik JR
    Adv Dent Res; 2006 Apr; 19(1):29-35. PubMed ID: 16672546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues.
    Wahl SM; Worley P; Jin W; McNeely TB; Eisenberg S; Fasching C; Orenstein JM; Janoff EN
    Am J Pathol; 1997 Apr; 150(4):1275-84. PubMed ID: 9094984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids.
    Kazmi SH; Naglik JR; Sweet SP; Evans RW; O'Shea S; Banatvala JE; Challacombe SJ
    Clin Vaccine Immunol; 2006 Oct; 13(10):1111-8. PubMed ID: 16928883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity.
    Jana NK; Gray LR; Shugars DC
    J Virol; 2005 May; 79(10):6432-40. PubMed ID: 15858026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral mucosal immunity and HIV/SIV infection.
    Lü FX; Jacobson RS
    J Dent Res; 2007 Mar; 86(3):216-26. PubMed ID: 17314252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innate immunity including epithelial and nonspecific host factors: workshop 1B.
    Weinberg A; Naglik JR; Kohli A; Tugizov SM; Fidel PL; Liu Y; Herzberg M
    Adv Dent Res; 2011 Apr; 23(1):122-9. PubMed ID: 21441493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism.
    Skott P; Lucht E; Ehnlund M; Björling E
    Oral Dis; 2002 May; 8(3):160-7. PubMed ID: 12108760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral innate immunity in HIV infection in HAART era.
    Nittayananta W; Tao R; Jiang L; Peng Y; Huang Y
    J Oral Pathol Med; 2016 Jan; 45(1):3-8. PubMed ID: 25639844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous salivary inhibitors of human immunodeficiency virus.
    Shugars DC; Alexander AL; Fu K; Freel SA
    Arch Oral Biol; 1999 Jun; 44(6):445-53. PubMed ID: 10401522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative proteomic analysis of the soluble immune factor environment of rectal and oral mucosa.
    Romas LM; Hasselrot K; Aboud LG; Birse KD; Ball TB; Broliden K; Burgener AD
    PLoS One; 2014; 9(6):e100820. PubMed ID: 24978053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of human beta-defensins in HIV infection.
    Weinberg A; Quiñones-Mateu ME; Lederman MM
    Adv Dent Res; 2006 Apr; 19(1):42-8. PubMed ID: 16672548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I.
    Shugars DC; Sauls DL; Weinberg JB
    Oral Dis; 1997 May; 3 Suppl 1():S70-2. PubMed ID: 9456661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.
    McNeely TB; Dealy M; Dripps DJ; Orenstein JM; Eisenberg SP; Wahl SM
    J Clin Invest; 1995 Jul; 96(1):456-64. PubMed ID: 7615818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretory leukocyte protease inhibitor (SLPI): oxidation of SLPI does not explain its variable anti-HIV activity.
    Konopka K; Shine N; Pretzer E; Düzgüneş N
    J Dent Res; 1999 Dec; 78(12):1773-6. PubMed ID: 10598905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.